Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:cholic acid
go back to main search page
Accession:CHEBI:16359 term browser browse the term
Definition:A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.
Synonyms:exact_synonym: 3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid
 related_synonym: (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid;   3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanate;   3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid;   Cholsaeure;   Formula=C24H40O5;   InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1;   InChIKey=BHQCQFFYRZLCQQ-OELDTZBJSA-N;   SMILES=[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@]([H])(CC[C@@]3([H])[C@]1([H])[C@H](O)C2)[C@H](C)CCC(O)=O
 alt_id: CHEBI:1694;   CHEBI:20223;   CHEBI:23210;   CHEBI:41494
 xref: Beilstein:2822009;   CAS:81-25-4;   DrugBank:DB02659;   Drug_Central:3096;   HMDB:HMDB0000619;   KEGG:C00695;   LINCS:LSM-5541;   LIPID_MAPS_instance:LMST04010001
 xref_mesh: MESH:D019826
 xref: MetaCyc:CHOLATE;   PDBeChem:CHD;   PMID:22770225;   Reaxys:2822009;   Wikipedia:Cholic_Acid
 cyclic_relationship: is_conjugate_acid_of CHEBI:29747


show annotations for term's descendants           Sort by:
 
cholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression
multiple interactions
ISO
EXP
Cholic Acid results in increased expression of ABCA1 mRNA
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCA1 mRNA
CTD PMID:14684380, PMID:15694933 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
JBrowse link
G Abca8 ATP binding cassette subfamily A member 8 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA CTD PMID:30996006 NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
JBrowse link
G Abca9 ATP binding cassette subfamily A member 9 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA CTD PMID:30996006 NCBI chr10:98,412,263...98,472,258
Ensembl chr10:98,412,263...98,469,799
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
decreases activity
multiple interactions
EXP
ISO
Cholic Acid results in increased expression of ABCB11 mRNA
Cholic Acid results in increased expression of ABCB11 mRNA; Cholic Acid results in increased expression of ABCB11 protein
Cholic Acid results in decreased activity of ABCB11 protein
Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB11 mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCB11 mRNA
CTD PMID:11438506, PMID:12971955, PMID:14684380, PMID:15466244, PMID:15694933, PMID:22540009, PMID:22961653, PMID:24014644, PMID:25055961, PMID:25582706, PMID:30996006 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression ISO Cholic Acid results in increased expression of ABCB1A mRNA; Cholic Acid results in increased expression of ABCB1A protein CTD PMID:11438506, PMID:17521389 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B increases expression ISO Cholic Acid results in increased expression of ABCB1B mRNA; Cholic Acid results in increased expression of ABCB1B protein CTD PMID:11438506 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 affects secretion
increases expression
multiple interactions
ISO ABCB4 affects the secretion of Cholic Acid
Cholic Acid results in increased expression of ABCB4 mRNA
epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB4 mRNA]
CTD PMID:12967592, PMID:22961653, PMID:25582706 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Cholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Cholic Acid results in increased expression of ABCC2 mRNA
Cholic Acid results in increased expression of ABCC2 mRNA; Cholic Acid results in increased expression of ABCC2 protein
CTD PMID:11438506, PMID:12971955, PMID:15694933, PMID:25055961, PMID:25582706 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression ISO Cholic Acid results in increased expression of ABCC3 mRNA CTD PMID:12971955, PMID:25055961, PMID:25582706 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA CTD PMID:30996006 NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression
multiple interactions
ISO Cholic Acid results in increased expression of ABCG5 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA
CTD PMID:25055961, PMID:25582706, PMID:30996006 NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression
multiple interactions
ISO Cholic Acid results in increased expression of ABCG8 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA
CTD PMID:25582706, PMID:30996006 NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
increases abundance
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Cholic Acid]
AHR gene mutant form results in increased secretion of Cholic Acid
AHR gene mutant form results in increased abundance of Cholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases abundance EXP AKR1C4 protein results in increased abundance of Cholic Acid CTD PMID:3468121 NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein; Diethylnitrosamine inhibits the reaction [Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein] CTD PMID:27151938 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA CTD PMID:30996006 NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Cholic Acid inhibits the reaction [Diethylnitrosamine results in increased cleavage of CASP3 protein] CTD PMID:27151938 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein] CTD PMID:16933029 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of CCND1 protein
Cholic Acid results in increased expression of CCND1 protein
CTD PMID:27151938 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression
multiple interactions
ISO Cholic Acid results in decreased expression of CDKN1A protein
[Diethylnitrosamine co-treated with Cholic Acid] results in decreased expression of CDKN1A protein
CTD PMID:27151938 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Chek1 checkpoint kinase 1 increases expression ISO Cholic Acid results in increased expression of CHEK1 protein CTD PMID:20025956 NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP
ISO
Cholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767, PMID:25582706 NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Cholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 increases expression ISO Cholic Acid results in increased expression of CYP2B10 mRNA CTD PMID:17521389 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
JBrowse link
G Cyp2b2 cytochrome P450, family 2, subfamily b, polypeptide 2 increases expression ISO Cholic Acid results in increased expression of CYP2B13 mRNA CTD PMID:17521389 NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO Cholic Acid results in increased expression of CYP2B9 mRNA CTD PMID:17521389 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP Cholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity EXP Cholic Acid results in decreased activity of CYP3A2 protein CTD PMID:8889968 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression
EXP
ISO
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CYP7A1 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CYP7A1 mRNA
Cholic Acid results in decreased expression of CYP7A1 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA
CTD PMID:12072388, PMID:14684380, PMID:15694933, PMID:17521389, PMID:20671298, PMID:22540009, PMID:25055961, PMID:25582706 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression ISO Cholic Acid results in decreased expression of CYP7B1 mRNA CTD PMID:20671298 NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 decreases expression ISO Cholic Acid results in decreased expression of CYP8B1 mRNA CTD PMID:17521389, PMID:25055961, PMID:25582706 NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression ISO Cholic Acid results in increased expression of FABP6 mRNA CTD PMID:25582706 NCBI chr10:29,191,621...29,196,593
Ensembl chr10:29,191,623...29,196,563
JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression
ISO [[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Cholic Acid results in increased expression of FGF15 mRNA
Cholic Acid results in increased expression of FGF19 mRNA
CTD PMID:22561792, PMID:25055961, PMID:25582706 NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
JBrowse link
G Fmo3 flavin containing dimethylaniline monoxygenase 3 increases expression ISO Cholic Acid results in increased expression of FMO3 mRNA CTD PMID:17521389 NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
JBrowse link
G Fmo4 flavin containing dimethylaniline monoxygenase 4 increases expression ISO Cholic Acid results in increased expression of FMO4 mRNA CTD PMID:17521389 NCBI chr13:80,685,385...80,703,575
Ensembl chr13:80,685,325...80,703,615
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression ISO Cholic Acid results in increased expression of FOSL1 protein CTD PMID:20025956 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression
ISO Cholic Acid binds to and results in increased activity of GPBAR1 protein
Cholic Acid results in increased expression of GPBAR1 mRNA
CTD PMID:18180267, PMID:25055961 NCBI chr 9:81,555,914...81,560,931
Ensembl chr 9:81,559,605...81,560,594
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP Cholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] CTD PMID:3783048 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression
multiple interactions
ISO
EXP
Cholic Acid results in increased expression of GSTA2 mRNA
Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]]
CTD PMID:3783048, PMID:17521389 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions EXP Cholic Acid binds to and results in decreased activity of GSTA4 protein CTD PMID:3954743 NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
JBrowse link
G Gsta6 glutathione S-transferase alpha 6 increases expression ISO Cholic Acid results in increased expression of GSTA2 mRNA CTD PMID:17521389 NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions EXP Cholic Acid binds to and results in decreased activity of GSTM1 protein CTD PMID:3954743 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions
increases expression
EXP
ISO
Cholic Acid binds to and results in decreased activity of GSTM2 protein
Cholic Acid results in increased expression of GSTM2 mRNA
CTD PMID:3954743, PMID:17521389 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression ISO Cholic Acid results in increased expression of GSTM3 mRNA CTD PMID:17521389 NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Hells helicase, lymphoid specific increases expression ISO Cholic Acid results in increased expression of HELLS protein CTD PMID:20025956 NCBI chr 1:257,901,856...257,953,889
Ensembl chr 1:257,766,691...257,949,183
Ensembl chr 1:257,766,691...257,949,183
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein] CTD PMID:30273964 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] CTD PMID:30273964 NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Cholic Acid CTD PMID:25061560 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of IL1B mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA] CTD PMID:12072388, PMID:27151938 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO Cholic Acid results in increased expression of IL1RL1 protein CTD PMID:20025956 NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] CTD PMID:30273964 NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA] CTD PMID:30273964 NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] CTD PMID:14684380, PMID:30273964 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Lrp2 LDL receptor related protein 2 increases expression
multiple interactions
ISO Cholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]
CTD PMID:15375181 NCBI chr 3:55,665,153...55,822,484
Ensembl chr 3:55,665,145...55,822,551
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Cholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases activity
ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK1 protein
Cholic Acid results in increased activity of MAPK1 protein
CTD PMID:27151938 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases activity
ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK3 protein
Cholic Acid results in increased activity of MAPK3 protein
CTD PMID:27151938 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression ISO Cholic Acid results in increased expression of MCM3 protein CTD PMID:20025956 NCBI chr 9:26,914,057...26,932,201
Ensembl chr 9:26,914,057...26,932,201
JBrowse link
G Mgst3 microsomal glutathione S-transferase 3 increases expression ISO Cholic Acid results in increased expression of MGST3 mRNA CTD PMID:17521389 NCBI chr13:85,601,499...85,622,392
Ensembl chr13:85,601,499...85,622,314
JBrowse link
G Mt1 metallothionein 1 increases expression ISO Cholic Acid results in increased expression of MT1 mRNA CTD PMID:17521389 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression ISO Cholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:25582706 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation
multiple interactions
ISO Cholic Acid results in increased phosphorylation of NFKBIA protein
Cholic Acid promotes the reaction [Diethylnitrosamine results in increased phosphorylation of NFKBIA protein]
CTD PMID:27151938 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Cholic Acid results in increased expression of NQO1 mRNA CTD PMID:25582706 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions
increases expression
EXP
ISO
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR0B2 mRNA
Cholic Acid results in increased expression of NR0B2 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]
CTD PMID:12072388, PMID:14684380, PMID:15694933, PMID:16002565, PMID:16269825, PMID:22540009, PMID:24189133, PMID:25055961, PMID:25582706 NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions EXP [Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H3 protein CTD PMID:14684380 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 affects binding
increases phosphorylation
increases expression
multiple interactions
increases activity
ISO
EXP
Cholic Acid binds to NR1H4 protein
Cholic Acid results in increased phosphorylation of NR1H4 protein
Cholic Acid results in increased expression of NR1H4 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA; Cholic Acid binds to and results in increased activity of NR1H4 protein; Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]; Cholic Acid results in increased phosphorylation of and results in increased activity of NR1H4 protein; NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]; NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]; NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]
[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; Cholic Acid analog binds to and results in increased activity of NR1H4 protein; Cholic Acid binds to and results in increased activity of NR1H4 protein
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H4 protein
CTD PMID:13130122, PMID:14684380, PMID:15375181, PMID:15694933, PMID:19965603, PMID:22540009, PMID:22561792, PMID:25055961, PMID:25496033, PMID:29968724, PMID:30996006 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression
increases activity
ISO Cholic Acid results in increased expression of NR1I2 mRNA
Cholic Acid metabolite results in increased activity of NR1I2 protein; Cholic Acid results in increased activity of NR1I2 protein
CTD PMID:25582706, PMID:27871908 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Cholic Acid results in increased expression of ORM1 protein CTD PMID:20025956 NCBI chr 5:79,179,668...79,182,820
Ensembl chr 5:79,179,417...79,182,820
JBrowse link
G Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 increases expression ISO Cholic Acid results in increased expression of PAPSS2 mRNA CTD PMID:17521389 NCBI chr 1:251,145,264...251,230,716
Ensembl chr 1:251,145,253...251,230,715
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression
multiple interactions
ISO Cholic Acid results in increased expression of PCNA protein
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of PCNA protein
CTD PMID:27151938 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO Cholic Acid results in increased expression of PIK3R5 protein CTD PMID:20025956 NCBI chr10:55,013,686...55,078,986
Ensembl chr10:55,013,703...55,080,421
JBrowse link
G Pon1 paraoxonase 1 decreases expression
multiple interactions
ISO
EXP
Cholic Acid results in decreased expression of PON1 mRNA; Cholic Acid results in decreased expression of PON1 protein
[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]
CTD PMID:16269825, PMID:30273964 NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
JBrowse link
G Por cytochrome p450 oxidoreductase increases expression
decreases abundance
ISO Cholic Acid results in increased expression of POR mRNA
POR gene mutant form results in decreased abundance of Cholic Acid
CTD PMID:17521389, PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Cholic Acid CTD PMID:29175453 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Cholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:119,910,461...119,963,065
Ensembl chr 4:119,910,478...119,959,173
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Cholic Acid promotes the reaction [Diethylnitrosamine results in increased expression of RELA protein] CTD PMID:27151938 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rif1 replication timing regulatory factor 1 increases expression ISO Cholic Acid results in increased expression of RIF1 protein CTD PMID:20025956 NCBI chr 3:37,599,540...37,648,818
Ensembl chr 3:37,599,728...37,647,631
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA CTD PMID:22540009, PMID:30996006 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
decreases expression
ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA
Cholic Acid results in decreased expression of SLC10A1 mRNA; Cholic Acid results in decreased expression of SLC10A1 protein
CTD PMID:11438506, PMID:16002565, PMID:17521389, PMID:22540009, PMID:25055961, PMID:25582706 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc10a2 solute carrier family 10 member 2 decreases expression ISO Cholic Acid results in decreased expression of SLC10A2 mRNA CTD PMID:25582706 NCBI chr16:90,324,420...90,350,254
Ensembl chr16:90,324,361...90,345,865
JBrowse link
G Slc22a20 solute carrier family 22 member 20 increases expression ISO Cholic Acid results in increased expression of SLC22A20 mRNA CTD PMID:17521389 NCBI chr 1:221,327,608...221,344,367
Ensembl chr 1:221,328,711...221,343,889
JBrowse link
G Slc27a5 solute carrier family 27 member 5 multiple interactions ISO Cholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 1:65,576,599...65,587,192
Ensembl chr 1:65,576,535...65,587,186
JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Cholic Acid results in increased expression of SLC2A1 protein CTD PMID:20025956 NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
JBrowse link
G Slc51a solute carrier family 51 subunit alpha increases expression ISO Cholic Acid results in increased expression of SLC51A mRNA CTD PMID:25055961, PMID:25582706 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions
increases expression
ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA
Cholic Acid results in increased expression of SLC51B mRNA
CTD PMID:22540009, PMID:22961653, PMID:25055961, PMID:25582706 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO Cholic Acid results in increased expression of SLCO1A4 mRNA CTD PMID:17521389 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 increases uptake
increases expression
ISO SLCO1B2 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B2 mRNA
CTD PMID:16534140, PMID:20949553, PMID:25055961, PMID:25582706 NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions
increases uptake
ISO Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Cholic Acid] CTD PMID:24285294 NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
JBrowse link
G Sod3 superoxide dismutase 3 multiple interactions
increases expression
ISO NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA] CTD PMID:25496033 NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Cholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein] CTD PMID:29968724 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Stmn1 stathmin 1 increases expression ISO Cholic Acid results in increased expression of STMN1 protein CTD PMID:20025956 NCBI chr 5:152,680,412...152,686,807
Ensembl chr 5:152,680,407...152,686,806
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 increases expression ISO Cholic Acid results in increased expression of SULT1A1 mRNA CTD PMID:17521389 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation
increases expression
ISO SULT2A1 protein results in increased sulfation of Cholic Acid
Cholic Acid results in increased expression of SULT2A1 mRNA
CTD PMID:17521389, PMID:20102295, PMID:22961653 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Tfrc transferrin receptor increases expression ISO Cholic Acid results in increased expression of TFRC protein CTD PMID:20025956 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
ISO Cholic Acid results in increased expression of TNF mRNA
Diethylnitrosamine promotes the reaction [Cholic Acid results in increased expression of TNF mRNA]
CTD PMID:27151938 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vdr vitamin D receptor increases localization ISO Cholic Acid results in increased localization of VDR protein CTD PMID:20371703 NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Cholic Acid results in increased expression of VEGFA protein CTD PMID:20025956 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
glycocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport
multiple interactions
ISO ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
CTD PMID:15791618, PMID:32152650 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:81,741,342...81,757,806
Ensembl chr11:81,741,297...81,757,813
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 6:64,165,913...64,170,122
Ensembl chr 6:64,165,913...64,170,151
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:84,986,994...85,141,464
Ensembl chr17:84,986,991...85,141,210
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 3:67,538,289...67,578,308
Ensembl chr 3:67,538,289...67,578,306
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:160,325,088...160,352,874
Ensembl chr 5:160,325,107...160,352,927
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:28,466,892...28,501,013
Ensembl chr18:28,466,311...28,495,937
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:120,503,093...120,531,782
Ensembl chr 2:120,504,130...120,531,782
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:60,419,446...60,446,656
Ensembl chr 2:60,419,525...60,446,510
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr15:4,356,512...4,360,788
Ensembl chr15:4,356,261...4,360,564
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
JBrowse link
G Il10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:16,923,989...16,934,706
Ensembl chr12:16,923,990...16,934,706
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 8:116,012,126...116,046,012
Ensembl chr 8:116,012,121...116,045,954
JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 2:140,708,396...140,727,381
Ensembl chr 2:140,708,397...140,727,281
JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr19:43,508,416...43,535,050
Ensembl chr19:43,506,976...43,528,851
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions
ISO Glycocholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710, PMID:32152650 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:49,848,939...49,909,404
Ensembl chr13:49,850,189...49,911,202
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 4:173,732,196...174,102,502
Ensembl chr 4:173,732,248...174,102,496
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:178,940,515...179,010,257
Ensembl chr 1:178,940,516...179,010,257
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:250,709,812...250,744,216
Ensembl chr 2:250,709,439...250,744,196
JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666, PMID:32152650 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:44,289,247...44,348,691
Ensembl chr14:44,289,247...44,348,691
JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,178,785...1,216,573
Ensembl chr18:1,178,787...1,216,409
JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
JBrowse link
hyodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases secretion ISO AHR gene mutant form results in increased secretion of hyodeoxycholic acid CTD PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions EXP [CYP2D6 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of hyodeoxycholic acid CTD PMID:18039809 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of hyodeoxycholic acid CTD PMID:25061560 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation
affects metabolic processing
increases glycosylation
ISO UGT2B7 protein alternative form results in increased glucuronidation of hyodeoxycholic acid; UGT2B7 protein results in increased glucuronidation of hyodeoxycholic acid
UGT2B7 protein affects the metabolism of hyodeoxycholic acid
UGT2B7 protein results in increased glycosylation of hyodeoxycholic acid
CTD PMID:8423545, PMID:8517101, PMID:12527334, PMID:21415305 NCBI chr14:22,597,103...22,619,968 JBrowse link
sodium cholate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein CTD PMID:26606054 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein] CTD PMID:27394961 NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of BAX protein CTD PMID:27394961 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of BCL2 protein CTD PMID:27394961 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein] CTD PMID:27394961 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO
EXP
[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL2 mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA
CTD PMID:23665937, PMID:26606054 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO [eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL5 mRNA CTD PMID:23665937 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein] CTD PMID:27394961 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ces1d carboxylesterase 1D increases expression ISO Sodium Cholate results in increased expression of CES1 mRNA CTD PMID:9565681 NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
JBrowse link
G Cst3 cystatin C multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CST3 protein CTD PMID:26606054 NCBI chr 3:143,219,671...143,223,544
Ensembl chr 3:143,219,686...143,223,615
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NOX2 mRNA CTD PMID:26606054 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A2 protein CTD PMID:1627548 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in decreased expression of CYP7A1 mRNA CTD PMID:23665937 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of FABP1 protein CTD PMID:26606054 NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein] CTD PMID:27394961 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of GPX2 mRNA CTD PMID:26606054 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HAVCR1 mRNA CTD PMID:26606054 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HIF1A mRNA CTD PMID:26606054 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in decreased expression of HMGCR mRNA CTD PMID:23665937 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA CTD PMID:26606054 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of ICAM1 mRNA CTD PMID:23665937 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP
[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of IL1B mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA
CTD PMID:23665937, PMID:26606054 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein] CTD PMID:27394961 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein] CTD PMID:27394961 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO MET gene mutant form affects the susceptibility to [Cholesterol, Dietary co-treated with Sodium Cholate]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [[[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Lipids] which results in increased abundance of Thiobarbituric Acid Reactive Substances]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased abundance of Triglycerides]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Glutathione]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of Bile Acids and Salts]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased uptake of and results in increased oxidation of Lipids] CTD PMID:27394961 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Naglu N-acetyl-alpha-glucosaminidase multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NAGLU protein CTD PMID:26606054 NCBI chr10:88,979,363...88,986,879
Ensembl chr10:88,979,383...88,986,867
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein] CTD PMID:27394961 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nphs1 NPHS1 adhesion molecule, nephrin multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in decreased expression of NPHS1 mRNA CTD PMID:26606054 NCBI chr 1:88,922,346...88,950,560
Ensembl chr 1:88,922,433...88,950,559
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein] CTD PMID:27394961 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein] CTD PMID:27394961 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein] CTD PMID:27394961 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein] CTD PMID:27394961 NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of S100A8 mRNA CTD PMID:26606054 NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA] CTD PMID:23665937 NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
JBrowse link
G Soat2 sterol O-acyltransferase 2 multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA] CTD PMID:23665937 NCBI chr 7:143,754,892...143,767,989
Ensembl chr 7:143,754,892...143,767,989
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein] CTD PMID:27394961 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA CTD PMID:26606054 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TLR4 mRNA CTD PMID:26606054 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA CTD PMID:26606054 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein] CTD PMID:27394961 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA CTD PMID:26606054 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link
taurocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca8 ATP binding cassette subfamily A member 8 affects transport ISO ABCA8 protein affects the transport of Taurocholic Acid CTD PMID:12379217 NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 affects import
increases uptake
increases expression
multiple interactions
increases transport
increases export
affects transport
increases import
decreases uptake
affects secretion
ISO
EXP
ABCB11 protein affects the import of Taurocholic Acid
ABCB11 protein results in increased uptake of Taurocholic Acid
Taurocholic Acid results in increased expression of ABCB11 mRNA
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction [ABCB11 protein results in increased import of Taurocholic Acid]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Amiodarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Benzbromarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Celecoxib inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diclofenac inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diethylstilbestrol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Disulfiram inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Elacridar inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Felodipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fenofibrate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Imatinib Mesylate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indomethacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Isradipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid]; Lopinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Mifepristone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Naproxen inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; nefazodone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nelfinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nicardipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrendipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; olmesartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ranolazine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; repaglinide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosiglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Saquinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Silymarin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; simvastatin acid inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Spironolactone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfinpyrazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Terfenadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Tinidazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; tipranavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; verlukast inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
ABCB11 protein affects the transport of Taurocholic Acid
ABCB11 protein affects the transport of Taurocholic Acid; ABCB11 protein mutant form affects the transport of Taurocholic Acid
ABCB11 protein results in decreased uptake of Taurocholic Acid
ABCB11 protein affects the secretion of Taurocholic Acid
Taurocholic Acid results in increased expression of ABCB11 protein
Taurocholic Acid results in increased expression of and results in increased activity of ABCB11 protein; troglitazone inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; troglitazone sulfate inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]
CTD PMID:10617675, PMID:11113123, PMID:11179459, PMID:11557132, PMID:12518026, PMID:12642476, PMID:12644037, PMID:12865277, PMID:14672610, PMID:14724752, PMID:15465654, PMID:15791618, PMID:15901796, PMID:16039748, PMID:19223659, PMID:20147439, PMID:20829430, PMID:24014644, PMID:25862123, PMID:27160211, PMID:27676153, PMID:30639138, PMID:31348918 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression EXP
ISO
Taurocholic Acid results in increased expression of ABCB1 protein
Taurocholic Acid results in increased expression of ABCB1A mRNA
CTD PMID:11113123, PMID:27160211 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression EXP Taurocholic Acid results in increased expression of ABCB4 protein CTD PMID:11113123 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Taurocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases activity
increases expression
multiple interactions
EXP
ISO
Taurocholic Acid results in increased activity of ABCC2 protein; Taurocholic Acid results in increased activity of ABCC2 protein modified form
Taurocholic Acid results in increased expression of ABCC2 mRNA
Taurocholic Acid results in increased expression of and results in increased activity of ABCC2 protein
CTD PMID:12644037, PMID:15904671, PMID:27160211 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases activity
multiple interactions
increases uptake
affects transport
ISO
EXP
Taurocholic Acid results in increased activity of ABCC3 protein
4-cresylglucuronide promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]; hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]
ABCC3 protein affects the transport of Taurocholic Acid
CTD PMID:11557524, PMID:17569508, PMID:30639138 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression ISO Taurocholic Acid results in increased expression of ABCG2 mRNA CTD PMID:27160211 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurocholic Acid]
AHR gene mutant form results in increased secretion of Taurocholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]] CTD PMID:12388182 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Apoa1 apolipoprotein A1 decreases expression ISO Taurocholic Acid results in decreased expression of APOA1 protein CTD PMID:19445040 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
JBrowse link
G Apoa4 apolipoprotein A4 multiple interactions EXP [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein CTD PMID:6631239 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G Apoe apolipoprotein E multiple interactions EXP [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein] CTD PMID:18512153 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Blvra biliverdin reductase A increases expression ISO Taurocholic Acid results in increased expression of BLVRA mRNA CTD PMID:18706437 NCBI chr 3:119,552,550...119,577,796
Ensembl chr 3:119,561,290...119,577,806
JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression EXP Taurocholic Acid results in increased expression of BNIP3L mRNA; Taurocholic Acid results in increased expression of BNIP3L protein CTD PMID:14530762 NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
JBrowse link
G Casp3 caspase 3 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] CTD PMID:12388182 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] CTD PMID:12388182 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP9 protein] CTD PMID:12388182 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cav1 caveolin 1 increases secretion ISO CAV1 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Cav2 caveolin 2 increases secretion ISO CAV2 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] CTD PMID:21224055, PMID:28505368 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA] CTD PMID:21224055 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression ISO Taurocholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases expression ISO Taurocholic Acid results in increased expression of CCL4 mRNA CTD PMID:21224055 NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 increases expression ISO Taurocholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccl7 C-C motif chemokine ligand 7 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]
Taurocholic Acid results in increased expression of CCND1 mRNA; Taurocholic Acid results in increased expression of CCND1 protein
CTD PMID:18512153, PMID:18840136 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccne1 cyclin E1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cel carboxyl ester lipase multiple interactions ISO Taurocholic Acid inhibits the reaction [Polyphenols results in decreased activity of CEL protein] CTD PMID:16099206 NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
JBrowse link
G Cftr CF transmembrane conductance regulator affects uptake
increases activity
ISO CFTR protein mutant form affects the uptake of Taurocholic Acid
Taurocholic Acid results in increased activity of CFTR protein
CTD PMID:15099439, PMID:16037545 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO Taurocholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO Taurocholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 increases expression ISO Taurocholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA] CTD PMID:21224055 NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression ISO Taurocholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr10:57,060,005...57,064,600
Ensembl chr10:57,060,007...57,064,600
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of CXCL2 mRNA; Taurocholic Acid results in increased expression of CXCL2 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of CXCL1 mRNA
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]
CTD PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP Taurocholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767 NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Taurocholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP Taurocholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity EXP Taurocholic Acid results in decreased activity of CYP3A2 protein CTD PMID:8889968 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression
ISO
EXP
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA] CTD PMID:7832767, PMID:16284190 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression
EXP Taurocholic Acid results in decreased activity of CYP7B1 protein
Taurocholic Acid results in decreased expression of CYP7B1 mRNA
CTD PMID:12029625 NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] CTD PMID:26518876 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of EGR1 mRNA; Taurocholic Acid results in increased expression of EGR1 protein
CTD PMID:21224055 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurocholic Acid CTD PMID:29906468 NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression
ISO [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA
Taurocholic Acid results in increased expression of FGF15 mRNA
CTD PMID:16284190 NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
JBrowse link
G Hgf hepatocyte growth factor increases uptake EXP HGF protein results in increased uptake of Taurocholic Acid CTD PMID:18031729 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha increases secretion ISO HNF4A protein results in increased secretion of Taurocholic Acid CTD PMID:27160211 NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
increases expression
EXP
ISO
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of ICAM1 mRNA; Taurocholic Acid results in increased expression of ICAM1 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
CTD PMID:19237016, PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Il10 interleukin 10 increases expression
increases abundance
ISO Taurocholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in increased abundance of Taurocholic Acid
CTD PMID:21224055, PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
decreases import
ISO
EXP
Taurocholic Acid results in increased expression of IL1B mRNA
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid
IL1B protein results in decreased import of Taurocholic Acid
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
Taurocholic Acid results in increased expression of IL1B mRNA; Taurocholic Acid results in increased expression of IL1B protein
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]
CTD PMID:21224055, PMID:25604657, PMID:30876886 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions
decreases import
increases expression
EXP
ISO
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
IL6 protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
Taurocholic Acid results in increased expression of IL6 mRNA; Taurocholic Acid results in increased expression of IL6 protein
CTD PMID:20035747, PMID:20382593, PMID:25604657, PMID:26518876, PMID:30876886 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Kl Klotho multiple interactions ISO Taurocholic Acid inhibits the reaction [KL protein results in increased hydrolysis of Glucuronides] CTD PMID:14701853 NCBI chr12:942,974...987,206
Ensembl chr12:943,006...987,551
JBrowse link
G Klf4 Kruppel like factor 4 increases expression ISO Taurocholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Taurocholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein] CTD PMID:26518876 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:18512153, PMID:26518876 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein] CTD PMID:28505368 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein] CTD PMID:28505368 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mir488 microRNA 488 increases expression ISO Taurocholic Acid results in increased expression of MIR488 mRNA CTD PMID:28851649 NCBI chr13:76,198,593...76,198,671
Ensembl chr13:76,198,593...76,198,671
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
increases expression
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein]
Taurocholic Acid results in increased expression of MMP2 mRNA; Taurocholic Acid results in increased expression of MMP2 protein
CTD PMID:26518876 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein]
Taurocholic Acid results in increased expression of MMP9 mRNA; Taurocholic Acid results in increased expression of MMP9 protein
CTD PMID:26518876 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity
increases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]
Taurocholic Acid results in increased expression of MPO protein
CTD PMID:16440434, PMID:20035747, PMID:25604657 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of MYC protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA
Taurocholic Acid results in increased expression of MYC mRNA
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]
CTD PMID:18512153, PMID:27151938, PMID:30556042 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nanog Nanog homeobox increases expression ISO Taurocholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression ISO Taurocholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:27160211 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein]
Taurocholic Acid results in decreased expression of NFKBIA mRNA; Taurocholic Acid results in decreased expression of NFKBIA protein
CTD PMID:25604657 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nfkbib NFKB inhibitor beta multiple interactions
decreases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
Taurocholic Acid results in decreased expression of NFKBIB mRNA; Taurocholic Acid results in decreased expression of NFKBIB protein
CTD PMID:25604657 NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
EXP [Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] CTD PMID:16389574 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression ISO Taurocholic Acid results in increased expression of NR0B2 mRNA CTD PMID:18706437 NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
affects response to substance
affects abundance
increases expression
increases export
increases activity
ISO epiallopregnanolone sulfate inhibits the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; GW 4064 promotes the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; Taurocholic Acid binds to and results in increased activity of NR1H4 protein
NR1H4 protein affects the susceptibility to Taurocholic Acid
NR1H4 protein affects the abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1H4 mRNA
Taurocholic Acid results in increased activity of NR1H4 protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA; [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]
CTD PMID:16284190, PMID:17567710, PMID:18706437, PMID:19445040, PMID:22961653, PMID:27160211, PMID:28505368, PMID:30556042 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression ISO Taurocholic Acid results in increased expression of NR1I2 mRNA CTD PMID:18706437, PMID:27160211 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions
increases expression
ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene binds to and affects the activity of NR1I3 protein] which results in decreased abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1I3 mRNA
CTD PMID:26984780, PMID:27160211 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Pnlip pancreatic lipase increases activity
multiple interactions
EXP Taurocholic Acid results in increased activity of PNLIP protein
orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]
CTD PMID:11668201 NCBI chr 1:279,798,187...279,811,372
Ensembl chr 1:279,798,187...279,811,372
JBrowse link
G Pon1 paraoxonase 1 multiple interactions
decreases expression
ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO Taurocholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:29175453 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of PTGS2 mRNA
Taurocholic Acid results in increased expression of PTGS2 protein
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; MK 2206 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]
CTD PMID:21224055, PMID:26518876 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Taurocholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:119,910,461...119,963,065
Ensembl chr 4:119,910,478...119,959,173
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases phosphorylation
affects localization
EXP
ISO
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein]
Taurocholic Acid results in increased phosphorylation of RELA protein
Taurocholic Acid affects the localization of RELA protein modified form
JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form]
CTD PMID:25604657, PMID:26518876 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G S1pr2 sphingosine-1-phosphate receptor 2 multiple interactions ISO S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; Taurocholic Acid results in increased activity of and results in increased uptake of S1PR2 protein CTD PMID:26518876 NCBI chr 8:21,984,914...21,995,806
Ensembl chr 8:21,984,914...21,995,806
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA] CTD PMID:28505368 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
increases expression
increases transport
increases import
increases uptake
EXP
ISO
Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLC10A1 mRNA
4-cresol sulfate inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; [Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid; Acetamides analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Acetanilides analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Anthraquinones analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; bisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; bisphenol F inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Piperazines analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Sodium deficiency inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]; Sulfobromophthalein inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; tetrabromobisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; tetrahydrophthalamic acid analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]
CTD PMID:19464309, PMID:22641618, PMID:23850984, PMID:25106415, PMID:25319728, PMID:25862123, PMID:27160211, PMID:27450509, PMID:27676153, PMID:27989701, PMID:29024779, PMID:30639138 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc10a2 solute carrier family 10 member 2 multiple interactions
increases transport
increases uptake
EXP
ISO
Bile Acids and Salts inhibits the reaction [SLC10A2 protein results in increased uptake of Taurocholic Acid]
Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid]
CTD PMID:19464309, PMID:25466967 NCBI chr16:90,324,420...90,350,254
Ensembl chr16:90,324,361...90,345,865
JBrowse link
G Slc19a1 solute carrier family 19 member 1 multiple interactions
decreases activity
EXP Taurocholic Acid inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate]
Taurocholic Acid results in decreased activity of SLC19A1 protein
CTD PMID:14612385 NCBI chr20:12,334,675...12,354,517
Ensembl chr20:12,334,676...12,352,377
JBrowse link
G Slc22a6 solute carrier family 22 member 6 multiple interactions ISO Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:11602689 NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
JBrowse link
G Slc22a8 solute carrier family 22 member 8 affects transport ISO SLC22A8 protein affects the transport of Taurocholic Acid CTD PMID:11306713 NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
JBrowse link
G Slc23a1 solute carrier family 23 member 1 increases expression ISO Taurocholic Acid results in increased expression of SLC23A1 mRNA CTD PMID:18706437 NCBI chr18:28,413,910...28,428,133
Ensembl chr18:28,414,009...28,428,117
JBrowse link
G Slc23a2 solute carrier family 23 member 2 increases expression ISO Taurocholic Acid results in increased expression of SLC23A2 mRNA CTD PMID:18706437 NCBI chr 3:124,632,491...124,842,225
Ensembl chr 3:124,632,492...124,724,252
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects uptake
multiple interactions
increases uptake
increases expression
affects transport
ISO
EXP
SLCO1A4 protein affects the uptake of Taurocholic Acid
Bile Acids and Salts inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1A4 mRNA
SLCO1A4 protein affects the transport of Taurocholic Acid
CTD PMID:19464309, PMID:19833843, PMID:21561886, PMID:27160211 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions
increases expression
increases uptake
EXP
ISO
Bile Acids and Salts inhibits the reaction [SLCO1B3 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1B2 mRNA
Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]
CTD PMID:19464309, PMID:26134461, PMID:27160211, PMID:30639138 NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions
increases uptake
ISO Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Taurocholic Acid] CTD PMID:24285294 NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
Taurocholic Acid results in decreased expression of SOD1 mRNA; Taurocholic Acid results in decreased expression of SOD1 protein
CTD PMID:25604657 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression
decreases expression
ISO
EXP
[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]
Taurocholic Acid results in increased expression of SOD2 mRNA
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
CTD PMID:22316666, PMID:25604657 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sort1 sortilin 1 increases sulfation ISO SORT1 gene mutant form results in increased sulfation of Taurocholic Acid CTD PMID:28453831 NCBI chr 2:211,078,092...211,156,312
Ensembl chr 2:211,078,334...211,156,312
JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression ISO Taurocholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545
JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Taurocholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stat1 signal transducer and activator of transcription 1 increases phosphorylation
multiple interactions
EXP Taurocholic Acid results in increased phosphorylation of STAT1 protein
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT1 protein]
CTD PMID:19563079 NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein] CTD PMID:18512153 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases import
increases expression
EXP
ISO
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
TNF protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
Taurocholic Acid results in increased expression of TNF mRNA; Taurocholic Acid results in increased expression of TNF protein
CTD PMID:16389574, PMID:19080501, PMID:19237016, PMID:19563079, PMID:20035747, PMID:20382593, PMID:25604657, PMID:26518876, PMID:30876886 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions
decreases expression
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]
Taurocholic Acid results in decreased expression of VCAM1 protein
CTD PMID:21224055, PMID:26176423, PMID:28851649 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19787
    chemical entity 19787
      molecular entity 19784
        polyatomic entity 19697
          heteroatomic molecular entity 19622
            hydroxides 19068
              organic hydroxy compound 18634
                hydroxy-5beta-cholanic acid 915
                  trihydroxy-5beta-cholanic acid 251
                    cholic acid 250
                      (23S)-methyl-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid 0
                      3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate 0
                      N-(2-phosphonoethyl)cholamide 0
                      S-choloyl-4'-phosphopantetheine 0
                      cholate salt + 41
                      cholic acid 24-O-(beta-D-glucuronide) 0
                      choloyl-CoA 0
                      glycochenodeoxycholic acid 7-sulfate 0
                      glycocholic acid 89
                      hyodeoxycholic acid + 4
                      murideoxycholic acid 0
                      taurocholic acid 108
                      taurohyocholic acid 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19787
    subatomic particle 19784
      composite particle 19784
        hadron 19784
          baryon 19784
            nucleon 19784
              atomic nucleus 19784
                atom 19784
                  main group element atom 19672
                    p-block element atom 19672
                      carbon group element atom 19574
                        carbon atom 19563
                          organic molecular entity 19563
                            organic molecule 19488
                              organic cyclic compound 19285
                                organic polycyclic compound 16384
                                  steroid 12788
                                    steroid fundamental parent 12403
                                      cholane 916
                                        cholanoid 916
                                          cholanic acids 915
                                            cholanic acid 915
                                              5beta-cholanic acid 915
                                                hydroxy-5beta-cholanic acid 915
                                                  trihydroxy-5beta-cholanic acid 251
                                                    cholic acid 250
                                                      (23S)-methyl-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid 0
                                                      3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate 0
                                                      N-(2-phosphonoethyl)cholamide 0
                                                      S-choloyl-4'-phosphopantetheine 0
                                                      cholate salt + 41
                                                      cholic acid 24-O-(beta-D-glucuronide) 0
                                                      choloyl-CoA 0
                                                      glycochenodeoxycholic acid 7-sulfate 0
                                                      glycocholic acid 89
                                                      hyodeoxycholic acid + 4
                                                      murideoxycholic acid 0
                                                      taurocholic acid 108
                                                      taurohyocholic acid 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.